ArticlePloS one2021

Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.

Evelyn M Mrozek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.